For the quarter ending 2025-12-31, INBS made $896,774 in revenue. -$2,677,590 in net income. Net profit margin of -298.58%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Revenue | 896,774 | 1,111,797 | 843,884 | 728,867 |
| Cost of revenue (exclusive of amortization shown separately below) | 437,035 | 593,506 | 508,307 | 387,499 |
| Gross profit | 459,739 | 518,291 | 335,577 | 341,368 |
| Government support income | 72,720 | 193,267 | 383,862 | 173,271 |
| Selling, general and administrative expenses | 2,337,041 | 2,659,824 | 2,718,229 | 2,407,558 |
| Development and regulatory approval expenses | 522,113 | 486,169 | 582,466 | 358,351 |
| Depreciation and amortization | 281,896 | 303,378 | 300,298 | 301,978 |
| Impairment of long-lived assets | 27,147 | 261,780 | 55,015.5 | - |
| Total operating expenses | 3,168,197 | 3,711,151 | 3,821,055 | 3,067,887 |
| Loss from operations | -2,635,738 | -2,999,593 | -3,101,616 | -2,553,248 |
| Interest expense | 56,209 | 3,903 | 10,061 | 15,000 |
| Realized foreign exchange loss | - | - | 3 | -113 |
| Fair value gain on revaluation of financial instrument | - | - | 0 | - |
| Interest income | 5,334 | 8,504 | 9,058 | 17,687 |
| Total other income (expense), net | -50,875 | 4,601 | -1,000 | 2,574 |
| Net loss | -2,686,613 | -2,994,992 | -3,102,616 | -2,550,674 |
| Net loss attributable to non-controlling interest | -9,023 | -11,986 | -12,512 | -7,148 |
| Net loss attributable to intelligent bio solutions inc | -2,677,590 | -2,983,006 | -3,090,104 | -2,543,526 |
| Net loss per share, basic | -2.82 | -0.35 | -0.36 | -0.44 |
| Net loss per share, diluted | -2.82 | -0.35 | -0.36 | -0.44 |
| Weighted average shares outstanding, basic | 950,829 | 8,546,934 | -8,845,173 | 5,771,911 |
| Weighted average shares outstanding, diluted | 950,829 | 8,546,934 | -8,845,173 | 5,771,911 |
INTELLIGENT BIO SOLUTIONS INC. (INBS)
INTELLIGENT BIO SOLUTIONS INC. (INBS)